News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexo AB Release: First Patient Dosed in New Phase III Study Targeted Towards a Future Clinical Indication Expansion for Zubsolv


6/17/2013 9:03:28 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Uppsala, Sweden – June 17, 2013 - Orexo AB announces today that the first patient has been dosed with Zubsolv in a phase III study for a new clinical indication for Zubsolv.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Orexo AB
 
 
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES